Harnessing Immune Synergy
Next-Gen T Cell Therapies for Cancer
We are an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Our proprietary approach to T cell engineering integrates desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, designed to engage the body's full immune repertoire for optimized cancer therapy. Our novel cellular immunotherapy platform, which redirects patient-derived T cells to eliminate tumors by employing phagocytic mechanisms, creates Chimeric Engulfment Receptor T cells (“CER-T”). We believe CER-T cells will offer greater therapeutic application than currently approved chimeric antigen receptor (“CAR”) T cell therapies, spanning both hematological malignancies and solid tumors.
